Qingdao Baheal Medical INC. (SHE:301015)

Market Cap	11.17B -17.6%
Revenue (ttm)	7.31B -6.9%
Net Income	536.22M +18.6%
EPS	1.00 +17.2%
Shares Out	525.62M
PE Ratio	21.32
Forward PE	20.57
Dividend	0.57 (2.69%)
Ex-Dividend Date	Jun 1, 2026

Volume	6,914,745
Open	23.83
Previous Close	22.42
Day's Range	21.22 - 23.83
52-Week Range	18.40 - 28.77
Beta	0.20
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About SHE:301015

Qingdao Baheal Medical INC. engages in the research and development, production, wholesale, and retail of pharmaceutical products in China, the United States, Hong Kong, and internationally. The company offers bone health drugs under the D-Cal brand name; digestive drugs under the Mite brand name; and liver disease drugs under the Fuzhenghuayu brand name. It also provides tumor and other severe drugs under the Utidelon, Gore Ning, Mai Ruibei, and Hai Ruisi brand names; diabetes drugs under the Naida, Feburic, and Naite brand names; and medical ...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 2005
• Employees: 2,493
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301015

Financial Performance

In 2025, SHE:301015's revenue was 7.51 billion, a decrease of -7.26% compared to the previous year's 8.09 billion. Earnings were 474.69 million, a decrease of -31.36%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 22, 2026

Data Sources Report a data error